121 related articles for article (PubMed ID: 11922198)
1. Evaluation of lipid profile, macular toxicity and clinical manifestations according to APO E genotype in systemic lupus erythematosus and rheumatoid arthritis patients treated with chloroquine.
Vázquez-Del Mercado M; Muñoz-Valle JF; Santos A; Bernard-Medina AG; Martínez-Bonilla G; Paczka JA; Ruiz-García H; Orozco-Alcalá J; Orozco-Barocio G; Quezada-Arellano D; Gurrola-Díaz C; Nuño-González P; Best-Aguilera CR; Chávez-Castellanos R; Panduro A
Scand J Rheumatol; 2002; 31(1):32-7. PubMed ID: 11922198
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism of the beta3-adrenergic receptor and lipid profile in patients with rheumatoid arthritis and systemic lupus erythematosus treated with chloroquine.
Muñoz-Valle JF; Vázquez-Del Mercado M; Ruiz-Quezada S; Oregón-Romero E; Navarro-Hernández RE; Ramírez-Barragán J; Martínez-Bonilla G; Bernard-Medina G; Bastidas-Ramírez BE; Ruiz-Madrigal B; Panduro A
Rheumatol Int; 2003 May; 23(3):99-103. PubMed ID: 12739037
[TBL] [Abstract][Full Text] [Related]
3. [Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses].
Rüther K; Foerster J; Berndt S; Schroeter J
Ophthalmologe; 2007 Oct; 104(10):875-9. PubMed ID: 17653725
[TBL] [Abstract][Full Text] [Related]
4. [Antimalarial's retinopaty remains a current threat].
Chiffoleau A; Guillet A; Zanlonghi X; Jolliet P
Presse Med; 2009 Apr; 38(4):662-3. PubMed ID: 19135848
[No Abstract] [Full Text] [Related]
5. Ocular lesions in rheumatoid arthritis and related disorders with particular reference to retinopathy. A study of 741 patients treated with and without chloroquine drugs.
SCHERBEL AL; MACKENZIE AH; NOUSEK JE; ATDJIAN M
N Engl J Med; 1965 Aug; 273(7):360-6. PubMed ID: 21417082
[No Abstract] [Full Text] [Related]
6. Chloroquine-induced bull's eye maculopathy.
Lai WW; Lam DS
Hong Kong Med J; 2005 Feb; 11(1):55-7. PubMed ID: 15687518
[TBL] [Abstract][Full Text] [Related]
7. Electrophysiological and SD-OCT findings in patients receiving chloroquine therapy in relation to cumulative dosage and duration of treatment.
Bertoli F; Šuštar M; Jarc Vidmar M; Perovšek D; Brecelj J; Markelj Š; Jaki Mekjavić P; Šuput D; Tomšič M; Isola M; Battistella C; Lanzetta P; Hawlina M
Doc Ophthalmol; 2020 Aug; 141(1):1-14. PubMed ID: 31927702
[TBL] [Abstract][Full Text] [Related]
8. Macular sensitivity changes for detection of chloroquine toxicity in asymptomatic patient.
Angi M; Romano V; Valldeperas X; Romano F; Romano MR
Int Ophthalmol; 2010 Apr; 30(2):195-7. PubMed ID: 19165421
[TBL] [Abstract][Full Text] [Related]
9. Is chloroquine obsolete in treatment of rheumatic disease?
Marks JS; Power BJ
Lancet; 1979 Feb; 1(8112):371-3. PubMed ID: 85016
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiologic findings in chloroquine maculopathy.
Halfeld Furtado de Mendonça R; Maia OO; Yukihiko Takahashi W
Doc Ophthalmol; 2007 Sep; 115(2):117-9. PubMed ID: 17562091
[TBL] [Abstract][Full Text] [Related]
11. Retinal disorders in northern Brazilian patients treated with chloroquine assessed by multifocal ERG.
Raster M; Horn F; Jünemann A; Rosa AA; Souza GS; Gomes BD; Lima MG; Silveira LC; Kremers J
Doc Ophthalmol; 2011 Apr; 122(2):77-86. PubMed ID: 21290166
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients.
Huang QR; Danis V; Lassere M; Edmonds J; Manolios N
Rheumatology (Oxford); 1999 Jul; 38(7):645-51. PubMed ID: 10461479
[TBL] [Abstract][Full Text] [Related]
13. Ocular side effects of chloroquine in patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma.
Leecharoen S; Wangkaew S; Louthrenoo W
J Med Assoc Thai; 2007 Jan; 90(1):52-8. PubMed ID: 17621733
[TBL] [Abstract][Full Text] [Related]
14. Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis.
Telek HH; Yesilirmak N; Sungur G; Ozdemir Y; Yesil NK; Ornek F
Doc Ophthalmol; 2017 Dec; 135(3):187-194. PubMed ID: 28852896
[TBL] [Abstract][Full Text] [Related]
15. [Maculopathy in long-term chloroquine therapy].
Wölfelschneider P; Kohen L; Wiedemann P
Ophthalmologe; 1998 Mar; 95(3):186-7. PubMed ID: 9578699
[No Abstract] [Full Text] [Related]
16. [The ERG contribution in early diagnosis of chloroquine and hydroxychloroquine maculopathy].
Karkanová M; Matusková V; Vlková E; Dosková H; Uhmannová R
Cesk Slov Oftalmol; 2010 Apr; 66(2):62-6. PubMed ID: 20925239
[TBL] [Abstract][Full Text] [Related]
17. Association of CD4 enhancer gene polymorphisms with rheumatoid arthritis and systemic lupus erythematosus in Taiwan.
Lo SF; Wan L; Lin HC; Huang CM; Tsai FJ
J Rheumatol; 2008 Nov; 35(11):2113-8. PubMed ID: 19004052
[TBL] [Abstract][Full Text] [Related]
18. Clinically evident chloroquine toxicity undetected by multifocal electroretinogram.
Burnett HK; Somani R
Can J Ophthalmol; 2012 Oct; 47(5):e31-3. PubMed ID: 23036562
[No Abstract] [Full Text] [Related]
19. Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy).
Grassmann F; Bergholz R; Mändl J; Jägle H; Ruether K; Weber BH
BMC Ophthalmol; 2015 Mar; 15():18. PubMed ID: 25884411
[TBL] [Abstract][Full Text] [Related]
20. Images in clinical medicine. Bull's-eye maculopathy.
Nogueira HM; Gama RD
N Engl J Med; 2009 May; 360(21):2224. PubMed ID: 19458367
[No Abstract] [Full Text] [Related]
[Next] [New Search]
